About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Raf1tm1.1Bgn
targeted mutation 1.1, Benjamin G Neel
MGI:5003364
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
ht1
Raf1tm1.1Bgn/Raf1+ involves: 129S6/SvEvTac * C57BL/6NCr MGI:5003451


Genotype
MGI:5003451
ht1
Allelic
Composition
Raf1tm1.1Bgn/Raf1+
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6NCr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Raf1tm1.1Bgn mutation (1 available); any Raf1 mutation (117 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Raf1tm1.1Bgn/Raf1+ mice show multiple Noonan syndrome phenotypes including short stature, facial dysmorphia and splenomegaly

mortality/aging
• following transverse aortic constriction

cardiovascular system
N
• fetal cardiomyocyte proliferation and valve development are normal
• at 8 weeks of age
• however, treatment with a MEK inhibitor rescues cardiomyocyte enlargement
• following transverse aortic constriction
• as early as 2 weeks after birth
• following transverse aortic constriction
• however, treatment with MEK inhibitor rescues cardiac hypertrophy
• increased left ventricular diastolic posterior wall thickness
• increased left ventricular internal end-diastolic dimension
• following transverse aortic constriction
• at 4 months, mice exhibit increased left ventricle internal end-diastolic dimension (LVIDd) compared with wild-type mice
• however, LVIDd is normal at 2 months of age and left ventricle internal end-systolic dimension is normal
• mice exhibit increased ventricular wall thickness compared with wild-type mice
• at 2 and 4 months of age, left ventricular diastolic posterior wall thickness is increased compared to in wild-type mice
• following transverse aortic constriction, mice exhibit severe cardiac interstitial fibrosis and perivascular fibrosis compared with wild-type mice
• following transverse aortic constriction
• mice exhibit abnormal cardiac function compared with wild-type mice
• however, treatment with a MEK inhibitor normalizes cardiac function
• as early as 2 weeks after birth
• at 2 and 4 months (J:172034)
• increased (J:189143)
• at 2 and 4 months, mice exhibit increased stroke volume compared with wild-type mice (J:172034)
• following transverse aortic constriction, mice exhibit increased stroke volume compared with wild-type mice (J:172034)
• following transverse aortic constriction
• at 2 and 4 months, mice exhibit increased ejection fraction and fractional shortening compared with wild-type mice (J:172034)
• however, cardiac relaxation is normal (J:172034)
• increased fractional shortening and ejection fraction (J:189143)
• at 4 months, mice exhibit decreased left ventricle pressure compared with wild-type mice
• following transverse aortic constriction
• following transverse aortic constriction, mice exhibit increased lethality, ventricular and left atrial enlargement, increased heart weight, severe interstitial fibrosis, perivascular fibrosis, deteriorating cardiac function (stroke volume and fractional shortening), decreased cardiac contractility, infarct, and fatal, functional decompensation in some mice compared with wild-type mice

immune system
• increasing in severity with age
• at 1 year of age
• at 1 year of age

craniofacial
• mice exhibit facial dysmorphia compared with wild-type mice
• however, treatment with a MEK inhibitory rescues facial dysmorphia
• blunt snout

growth/size/body
• as early as 2 weeks after birth
• following transverse aortic constriction
• however, treatment with MEK inhibitor rescues cardiac hypertrophy
• mice exhibit facial dysmorphia compared with wild-type mice
• however, treatment with a MEK inhibitory rescues facial dysmorphia
• blunt snout
• at weaning
• however, mice treated with a MEK inhibitor normalizes weight
• however, mice treated with a MEK inhibitor normalizes length
• increasing in severity with age

homeostasis/metabolism
• following transverse aortic constriction, mice exhibit increased lethality, ventricular and left atrial enlargement, increased heart weight, severe interstitial fibrosis, perivascular fibrosis, deteriorating cardiac function (stroke volume and fractional shortening), decreased cardiac contractility, infarct, and fatal, functional decompensation in some mice compared with wild-type mice

muscle
• at 8 weeks of age
• however, treatment with a MEK inhibitor rescues cardiomyocyte enlargement
• as early as 2 weeks after birth
• following transverse aortic constriction
• at 2 and 4 months, mice exhibit increased ejection fraction and fractional shortening compared with wild-type mice (J:172034)
• however, cardiac relaxation is normal (J:172034)
• increased fractional shortening and ejection fraction (J:189143)

skeleton

vision/eye

hematopoietic system
• increasing in severity with age
• myeloid progenitors are expanded compared to in wild-type mice
• at 1 year of age
• at 1 year of age

cellular
• following transverse aortic constriction

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Noonan syndrome 5 DOID:0060583 OMIM:611553
J:172034





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory